Bimekizumab, a novel biologic immunotherapy, exerts its therapeutic effect in plaque psoriasis by selectively neutralizing IL-17A and IL-17F (Koppu et al., 2022). The gene discussed is IL17F; the disease is psoriasis vulgaris.